Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Efficacy and Safety of Dolutegravir Plus Emtricitabine vs Combined Antiretroviral Therapy for the Maintenance of HIV Suppression: Results Through Week 144 of the SIMPL’HIV Trial

Open Forum Infectious Diseases(2024)10.1093/ofid/ofae618Source: DataRank Database

Efficacy and Safety of Dolutegravir Plus Emtricitabine vs Combined Antiretroviral Therapy for the Maintenance of HIV Suppression: Results Through Week 144 of the SIMPL’HIV Trial is a research paper published in Open Forum Infectious Diseases (2024). On theSindex it has a DataRank of 0. It has been cited 1 time.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access1 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 0.30)OA: goldTopics (18)IDs (PubMed, PMC, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (21)

Delphine Sculier ORCID,Gilles Wandeler ORCID,Sabine Yerly ORCID,Marcel Stoeckle ORCID,Enos Bernasconi ORCID

Live enrichment

PubMed:39507885 PMC:PMC11540136 OpenAlex:https://openalex.org/W4403445533

Swiss National Science Foundation

Grant: 166819

Swiss National Science Foundation

Grant: 17481

Swiss HIV Cohort Study

FWCI

0.30

Citation Percentile

0.6%

Citation Trend

2025

goldLicense: cc-by

journalhttps://doi.org/10.1093/ofid/ofae618

publisherhttps://doi.org/10.1093/ofid/ofae618

publisherhttps://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofae618/59788685/ofae618.pdf

publisherhttps://academic.oup.com/ofid/article-pdf/11/11/ofae618/60751184/ofae618.pdf

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39507885

Fields of Study

HIV/AIDS drug development and treatmentHIV Research and TreatmentHIV/AIDS Research and Interventions

Keywords

DolutegravirMedicineEmtricitabineAntiretroviral therapyHuman immunodeficiency virus (HIV)TenofovirInternal medicineOncologyViral loadVirologyQuality of lifePatient SatisfactionMaintenance TreatmentHiv-1 Dual TherapyDolutegravir + Emtricitabine